These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 36226408)

  • 21. Burden of Chemotherapy-Induced Febrile Neutropenia Hospitalizations in US Clinical Practice, by Use and Patterns of Prophylaxis with Colony-Stimulating Factor.
    Weycker D; Li X; Tzivelekis S; Atwood M; Garcia J; Li Y; Reiner M; Lyman GH
    Support Care Cancer; 2017 Feb; 25(2):439-447. PubMed ID: 27734153
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy.
    Wong SF; Chan HO
    Pharmacotherapy; 2005 Mar; 25(3):372-8. PubMed ID: 15843284
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Colony-stimulating factors for chemotherapy-induced febrile neutropenia.
    Mhaskar R; Clark OA; Lyman G; Engel Ayer Botrel T; Morganti Paladini L; Djulbegovic B
    Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD003039. PubMed ID: 25356786
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Overuse and underuse of pegfilgrastim for primary prophylaxis of febrile neutropenia.
    Zullo AR; Lou U; Cabral SE; Huynh J; Berard-Collins CM
    J Oncol Pharm Pract; 2019 Sep; 25(6):1357-1365. PubMed ID: 30124123
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Retrospective comparison of neutropenia in children with Ewing sarcoma treated with chemotherapy and granulocyte colony-stimulating factor (G-CSF) or pegylated G-CSF.
    Milano-Bausset E; Gaudart J; Rome A; Coze C; Gentet JC; Padovani L; Lacarelle B; André N
    Clin Ther; 2009; 31 Pt 2():2388-95. PubMed ID: 20110048
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Colony-stimulating factors for the management of neutropenia in cancer patients.
    Dale DC
    Drugs; 2002; 62 Suppl 1():1-15. PubMed ID: 12479591
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pegfilgrastim for the prevention of chemotherapy-induced febrile neutropenia in patients with solid tumors.
    Lambertini M; Ferreira AR; Del Mastro L; Danesi R; Pronzato P
    Expert Opin Biol Ther; 2015; 15(12):1799-817. PubMed ID: 26488491
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biosimilar filgrastim treatment patterns and prevention of febrile neutropenia: a prospective multicentre study in France in patients with solid tumours (the ZOHé study).
    Roché H; Eymard JC; Radji A; Prevost A; Diab R; Lamuraglia M; Soumoudronga RF; Gasnereau I; Toledano A
    BMC Cancer; 2018 Nov; 18(1):1127. PubMed ID: 30445935
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Two decades of pegfilgrastim: what have we learned? Where do we go from here?
    De Oliveira Brandao C; Lewis S; Sandschafer D; Crawford J
    Curr Med Res Opin; 2023 May; 39(5):707-718. PubMed ID: 36976784
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy, effectiveness and safety of long-acting granulocyte colony-stimulating factors for prophylaxis of chemotherapy-induced neutropenia in patients with cancer: a systematic review.
    Pfeil AM; Allcott K; Pettengell R; von Minckwitz G; Schwenkglenks M; Szabo Z
    Support Care Cancer; 2015 Feb; 23(2):525-45. PubMed ID: 25284721
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of primary granulocyte-colony stimulating factor prophylaxis on neutropenic toxicity and chemotherapy dose delivery in Chinese patients with breast cancer who received adjuvant docetaxel plus cyclophosphamide chemotherapy: a retrospective cohort study.
    Kwok CCH; Wong WH; Chan LL; Wong SPY; Wang F; Wong MCS; Tse SLA
    Hong Kong Med J; 2022 Dec; 28(6):438-446. PubMed ID: 36261264
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neutropenia-Associated Outcomes in Patients With Breast Cancer Receiving Myelosuppressive Chemotherapy With Reduced Doses of Pegfilgrastim.
    Moore DC; Gebru T; Pellegrino A; Fasan A; Patel J; Ringley JT
    J Pharm Pract; 2020 Dec; 33(6):779-783. PubMed ID: 30917723
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prophylaxis of chemotherapy-induced neutropenia and febrile neutropenia with lipegfilgrastim in patients with non-Hodgkin lymphoma (NADIR study).
    Wolff T; Schulz H; Losem C; Reichert D; Hurtz HJ; Sandner R; Harde J; Grebhardt S; Potthoff K; Mueller U; Fietz T
    Eur J Haematol; 2019 Feb; 102(2):174-181. PubMed ID: 30347466
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Effectiveness of Febrile Neutropenia Prophylaxis with Lipegfilgrastim in Routine Clinical Practice.
    Holubec L; Polivka J; Lisnerova L; Kubikova T; Safanda M
    In Vivo; 2017; 31(3):303-306. PubMed ID: 28438855
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of granulocyte colony stimulating factor as a secondary prophylaxis along with full-dose chemotherapy following a prior cycle of febrile neutropenia.
    Gupta S; Singh PK; Bhatt ML; Pant MC; Gupta R; Negi MP
    Biosci Trends; 2010 Oct; 4(5):273-8. PubMed ID: 21068482
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapeutic use of granulocyte colony-stimulating factor (G-CSF) in patients with febrile neutropenia: a comprehensive systematic review for clinical practice guidelines for the use of G-CSF 2022 from the Japan Society of Clinical Oncology.
    Tsuchihashi K; Ito M; Okumura Y; Nio K; Ozaki Y; Nishio H; Ichihara E; Miura Y; Endo M; Yano S; Maruyama D; Yoshinami T; Susumu N; Takekuma M; Motohashi T; Ochi N; Kubo T; Uchino K; Kimura T; Kamiyama Y; Nakao S; Tamura S; Nishimoto H; Kato Y; Sato A; Takano T; Baba E
    Int J Clin Oncol; 2024 Jun; 29(6):700-705. PubMed ID: 38696053
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Study design: two long-term observational studies of the biosimilar filgrastim Nivestim™ (Hospira filgrastim) in the treatment and prevention of chemotherapy-induced neutropenia.
    Kamioner D; Fruehauf S; Maloisel F; Cals L; Lepretre S; Berthou C
    BMC Cancer; 2013 Nov; 13():547. PubMed ID: 24237790
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative effectiveness of filgrastim, pegfilgrastim, and sargramostim as prophylaxis against hospitalization for neutropenic complications in patients with cancer receiving chemotherapy.
    Weycker D; Malin J; Barron R; Edelsberg J; Kartashov A; Oster G
    Am J Clin Oncol; 2012 Jun; 35(3):267-74. PubMed ID: 21378538
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical Outcomes of Treatment with Filgrastim Versus a Filgrastim Biosimilar and Febrile Neutropenia-Associated Costs Among Patients with Nonmyeloid Cancer Undergoing Chemotherapy.
    Schwartzberg LS; Lal LS; Balu S; Campbell K; Brekke L; DeLeon A; Elliott C; Korrer S
    J Manag Care Spec Pharm; 2018 Oct; 24(10):976-984. PubMed ID: 29687743
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Towards a comprehensive safety understanding of granulocyte-colony stimulating factor biosimilars in treating chemotherapy associated febrile neutropenia: Trends from decades of data.
    Rastogi S; Shukla S; Sharma AK; Sarwat M; Srivastava P; Katiyar T; Kalaiselvan V; Singh GN
    Toxicol Appl Pharmacol; 2020 May; 395():114976. PubMed ID: 32222375
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.